The relationship of the Fas 670 A/G gene polymorphism with cardiovascular risk factors in polycystic ovary syndrome (PCOS) patients

References

• Chang RJ. A practical approach to the diagnosis of polycystic ovary syndrome. Am J Obstet Gynecol 2004;191:713–717.
   PubMedGoogle Scholar
• King J. Polycystic ovary syndrome. J Midwifery Womens Health 2006;51:415–422.
   PubMed Web of Science ®Google Scholar
• Otto-Buczkowska E, Jarosz-Chobot P, Deja G. Early metabolic abnormalities – insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome. Przegl Lek 2006;63:234–238.
   PubMedGoogle Scholar
• Barutcuoglu B, Bozdemir AE, Dereli D, et al Increased serum neopterin levels in women with polycystic ovary syndrome. Ann Clin Lab Sci 2006;36:267–272.
   PubMed Web of Science ®Google Scholar
• Mizuno T, Zhong X, Rothstein TL. Fas-induced apoptosis in B cells. Apoptosis 2003;8:451–460.
   PubMed Web of Science ®Google Scholar
• Seo JC, Han SW, Yin CS, et al Evaluation of a Apo-1/Fas promoter polymorphism in Korean stroke patients. Exp Mol Med 2002;30:294–298.
   Google Scholar
• Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577–582.
   PubMed Web of Science ®Google Scholar
• Decker T, Kovarik P, Meinke A. GAS elements: a few nucleotides with a major impact on cytokine-induced gene expression. J Interferon Cytokine Res 1997;17:121–134.
   PubMed Web of Science ®Google Scholar
• Niino M, Kikuchi S, Fukazawa T, et al An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis. BMC Neurol 2002;21:2–8.
   Google Scholar
• Homburg R, Amsterdam A. Polysystic ovary syndrome – loss of the apoptotic mechanism in the ovarian follicles? J Endocrinol Invest 1998;21:552–557.
   PubMed Web of Science ®Google Scholar
• Cataldo NA, Dumesic DA, Goldsmith PC, et al Immunolocalization of Fas and Fas ligand in the ovaries of women with polycystic ovary syndrome: relationship to apoptosis. Hum Reprod 2000;15:1889–1897.
   PubMed Web of Science ®Google Scholar
• Honnma H, Endo T, Henmi H, et al Altered expression of Fas/Fas ligand/caspase 8 and membrane type 1-matrix metalloproteinase in atretic follicles within dehydroepiandrosterone-induced polycystic ovaries in rats. Apoptosis 2006;11:1525–1533.
   PubMed Web of Science ®Google Scholar
• Blanco-Colio LM, Martin-Ventura JL, de Teresa E, et al Increased soluble Fas plasma levels in subjects at high cardiovascular risk: atorvastatin on inflammatory markers (AIM) study, a substudy of ACTFAST. Arterioscler Thromb Vasc Biol 2007;27:168–174.
   PubMed Web of Science ®Google Scholar
• van der Meer IM, Oei HH, Hofman A, et al Soluble Fas, a mediator of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis. The Rotterdam Coronary Calcification Study. Atherosclerosis 2006;189:464–469.
   PubMed Web of Science ®Google Scholar
• Nasiek M, Kos-Kudla B, Ostrowska Z, et al Acute phase proteins: C-reactive protein and fibrinogen in young women with polycystic ovary syndrome. Pathophysiology 2006;14:23–28.
   PubMedGoogle Scholar
• Bickerton AS, Clark N, Meeking D, et al Cardiovascular risk in women with polycystic ovarian syndrome (PCOS). J Clin Pathol 2005;58:151–154.
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Hosker JP, Rudenski AS, et al Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–419.
   PubMed Web of Science ®Google Scholar
• Dokras A, Bochner M, Hollinrake E, et al Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 2005;106:131–137.
   PubMed Web of Science ®Google Scholar
• Cussons AJ, Stuckey BG, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006;185:227–239.
   PubMed Web of Science ®Google Scholar
• Lakhani K, Prelevic GM, Seifalian AM, et al Polycystic ovary syndrome, diabetes and cardiovascular disease: risks and risk factors. J Obstet Gynaecol 2006;24:613–621.
   Google Scholar
• Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005;90:5711–5716.
   PubMed Web of Science ®Google Scholar
• Fleischman A, Mansfield J. Diagnosis and treatment of polycystic ovarian syndrome and insulin resistance. Pediatr Ann 2005;34:733–738, 741–742.
   PubMedGoogle Scholar
• Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, et al Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women. Diabetologia 2003;46:625–633.
   PubMed Web of Science ®Google Scholar
• Imanishi T, Hano T, Sawamura T, et al Oxidized low density lipoprotein potentiation of Fas-induced apoptosis through lectin-like oxidized-low density lipoprotein receptor-1 in human umbilical vascular endothelial cells. Circ J 2002;66:1060–1064.
   PubMedGoogle Scholar
• Imanishi T, Hano T, Nishio I, et al Apoptosis of vascular smooth muscle cells is induced by Fas ligand derived from endothelial cells. Jpn Circ J 2001;65:556–560.
   PubMedGoogle Scholar
• Bolstad AI, Wargelius A, Nakken B, et al Fas and Fas ligand gene polymorphisms in primary Sjogren's syndrome. J Rheumatol 2000;27:2397–2405.
   PubMed Web of Science ®Google Scholar
• Bolstad AI, Eiken HG, Rosenlund B, et al Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjogren's syndrome. Arthritis Rheum 2003;48:174–185.
   PubMed Web of Science ®Google Scholar
• Kanemitsu S, Ihara K, Saifddin A, et al A functional polymorphism in fas (CD95/APO-1) gene promoter associated with systemic lupus erythematosus. J Rheumatol 2002;29:1183–1188.
   PubMed Web of Science ®Google Scholar
• Nolsoe RL, Kelly JA, Pociot F, et al Functional promoter haplotypes of the human FAS gene are associated with the phenotype of SLE characterized by thrombocytopenia. Genes Immune 2005;6:699–706.
   PubMedGoogle Scholar
• Latkovskis G, Licis N, Kalnins U. C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur J Immunogenet 2004;31:207–213.
   PubMedGoogle Scholar
• Morin-Papunen L, Rautio K, Ruokonen A, et al Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:4649–4654.
   PubMed Web of Science ®Google Scholar
• Kelly CC, Lyall H, Petrie JR, et al Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86:2453–2455.
   PubMed Web of Science ®Google Scholar